Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Associations of symptomatic OA may suggest roles of MMP1 expression and IL1R1 and VEGF pathways in OA pain.
|
30597276 |
2019 |
Degenerative polyarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lack of association between matrix metalloproteinase-1 gene rs1799750 polymorphism and osteoarthritis susceptibility: a meta-analysis.
|
30886066 |
2019 |
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of MMP-1 and -7 in serum were highest in DM-OA group.
|
29270923 |
2019 |
Degenerative polyarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, this case-control study confirms that <i>MMP-1</i> gene rs1799750 polymorphism increases the risk of knee OA in Chinese Han population.
|
30177524 |
2018 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polymerase chain reaction (PCR) results showed that both IL-1β and chemerin reduced the expression of the protective genes in OA (MMP-1, MMP-3, and MMP-13).
|
29949137 |
2018 |
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
IL-1β stimulus determined a significant regulation of survival, apoptotic ratio, as well as of gene expression and serum levels of MMP-1,-3,-13 and Col2a1 in OA chondrocytes compared to baseline.
|
30316071 |
2018 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Selected bioactives, sulforaphane, apigenin, isoliquiritigenin and luteolin, inhibited one or more interleukin-1-induced metalloproteinases implicated in OA (MMP1, MMP13, ADAMTS4, ADAMTS5).
|
30464238 |
2018 |
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Changes in matrix metalloproteinases (MMPs) and apoptosis genes (bax, caspase 3 and tnf-α) and OA-specific protein (MMP-1) expression in vitro and in vivo were detected by real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and immunohistochemistry.
|
30261492 |
2018 |
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results showed that CS-SM could protect articular cartilage in OA, inhibit the degradation of cartilage, decrease the apoptosis of chondrocytes, decline the content of interleukin-1, tumor necrosis factor-α and Prostaglandins E<sub>2</sub> in synovial fluid, down-regulate the protein expression of matrix metalloproteinase-1 and up-regulate the protein expression of tissue inhibitor of metalloproteinase-1.
|
29154876 |
2018 |
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, we demonstrated for the first time that Sanguinarine suppressed the expression of matrix metalloproteinase 1, 3, and 13, and A disintegrin and metalloproteinase with thrombospondin motifs-5 <i>in vitro</i>, <i>ex vivo</i>, and <i>in vivo</i>, indicating its potential usefulness in treating osteoarthritis.
|
28968958 |
2017 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, we demonstrate that treatment of macrophages with BCP crystals induces the production of the damage-associated molecule S100A8 and MMP1 in a Syk-dependent manner and that synovial fluid from OA patients together with BCP crystals exacerbates these effects.
|
28173838 |
2017 |
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
IL-1β reduced PRG4 expression in OA synoviocytes and rhPRG4 (100 μg/ml) treatment reversed this effect (p < 0.001). rhPRG4 (200 μg/ml) reduced basal gene expression of MMP-1, MMP-3, MMP-13, IL-6, IL-8, and PRG4 in OA synoviocytes, while increasing TIMP-2 and cycloxygenase-2 (COX2) expression (p < 0.001). rhPRG4 (200 μg/ml) reduced IL-1β induction of MMP-1, MMP-3, MMP-9, MMP-13, IL-6, IL-8, and COX2 expression in a CD44-dependent manner (p < 0.001).
|
28482921 |
2017 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we found that silibinin significantly inhibited the nterleukin-1β (IL-1β)-induced production of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-α (TNF-α) and IL-6, expression of cyclooxygenase2 (COX-2), inducible nitric oxide synthase (iNOS), matrix metalloproteinase-1 (MMP-1), MMP-3, MMP-13, a disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4) and ADAMTS-5, degradation of aggrecan and collagen-II in human OA chondrocytes.
|
29245931 |
2017 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We confirmed the increased secretion by nicotine of matrix metalloproteinase 1 and two proposed markers of OA, fibronectin, and chitinase 3-like protein 1.
|
25914226 |
2016 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the potential genetic contribution of the RAGE, S100A8, and MMP-1 genes to OA.
|
26436377 |
2015 |
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our study indicates that ETS-1 may contribute to RA progression by up-regulation of MMP1 and result in OA progression via up-regulating CD53.
|
26404854 |
2015 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that 2ccPA significantly reduces the pain response to OA by inducing hyaluronic acid production and suppressing MMP-1, -3, and -13 production in synoviocytes and chondrocytes.
|
25123228 |
2014 |
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using rabbit and human synovial fibroblast cell lines, we examined the effects of Cx43 overexpression and Cx43 siRNA-mediated knockdown on the gene expression of OA-associated matrix metalloproteinases (MMP1 and MMP13), aggrecanases (ADAMTS4 and ADAMTS5), and inflammatory factors (IL1, IL6 and PTGS2) by quantitative real time RT-PCR.
|
25496568 |
2014 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparative expression pattern analysis revealed the involvement of catabolic enzymes (MMP1, -2, -13, ADAM10), chemokines (IL8, CCL2, CXCL2, CXCL12, CCXL14), and genes associated with cell death (TNFSF10, PMAIPI, AHR) and skeletal development (GPNMB, FRZB) including transcription factors (WIF1, DLX5, TWIST1) and growth factors (IGFBP1, -3, TGFB1) consistent with published data from human OA cartilage.
|
24635637 |
2014 |
Degenerative polyarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the MMP1 and MMP3 haplotypes may represent genetic determinants for RA and OA in the Egyptian population.
|
21770773 |
2012 |
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nitrotyrosine expression in the subchondral bone region was decreased in the rebamipide-treated joints. mRNA expression of MMP-1, -3, and -13, and ADAMTS5 was attenuated in IL-1β-stimulated human OA chondrocytes.
|
22890185 |
2012 |
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Sesamol prevented the expression of MMP-1 and -9 in the cartilage of MIA-induced OA in rats.
|
21428299 |
2011 |
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PGE2 showed inhibitory effects on IL-1beta-induced MMP-1 and MMP-13 expression demonstrated by immunoblotting both in OA and normal chondrocytes, which was further confirmed by enzyme-linked immunosorbent assay and immunohistochemistry of explant cultures of articular cartilages.
|
19998410 |
2010 |
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of MMP1 mRNA was weak in OA samples, however, while expression of ADAMTS5 and APOL1 mRNAs was weak in the controls and some of the OA samples.
|
17966030 |
2007 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, we evaluated the role of PAR-2 on the synthesis of the major catabolic factors in OA cartilage, including metalloproteinase (MMP)-1 and MMP-13 and the inflammatory mediator cyclooxygenase 2 (COX-2), as well as the PAR-2-activated signalling pathways in OA chondrocytes.
|
18031579 |
2007 |